Literature DB >> 19845747

Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study.

M Jonsson1, H Zetterberg, E van Straaten, K Lind, S Syversen, A Edman, K Blennow, L Rosengren, L Pantoni, D Inzitari, A Wallin.   

Abstract

BACKGROUND AND
PURPOSE: White matter lesions (WMLs) caused by small vessel disease are common in elderly people and contribute to cognitive impairment. There are no established biochemical markers for WMLs. We aimed to study the relation between degree of WMLs rated on magnetic resonance imaging of the brain and cerebrospinal fluid (CSF) levels of structural biomarkers associated with Alzheimer's disease (AD) and subcortical vascular dementia.
METHODS: Fifty-three non-demented elderly individuals with WMLs were subjected to lumbar puncture. Degree of WMLs was rated using the Fazekas scale. Volumetric assessment of WMLs was performed. CSF samples were analyzed for the 40 and 42 amino acid fragments of amyloid beta, alpha- and beta-cleaved soluble amyloid precursor protein, total tau (T-tau), hyperphosphorylated tau (P-tau(181)), neurofilament light protein (NFL), sulfatide and CSF/Serum-albumin ratio.
RESULTS: Fifteen subjects had mild, 23 had moderate and 15 had severe degree of WMLs. CSF-NFL levels differed between the groups (P < 0.001) and correlated with the volume of WMLs (r = 0.477, P < 0.001). CSF sulfatide concentration displayed similar changes but less strongly. T-tau, P-tau(181) and the different amyloid markers as well as CSF/S-albumin ratio did not differ significantly between the groups.
CONCLUSIONS: The association of increased CSF-NFL levels with increasing severity of WMLs in non-demented subjects suggests that NFL is a marker for axonal damage in response to small vessel disease in the brain. This manifestation may be distinct from or earlier than the neurodegenerative process seen in AD, as reflected by the lack of association between WMLs and AD biomarkers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19845747     DOI: 10.1111/j.1468-1331.2009.02808.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  44 in total

Review 1.  Binswanger's disease: toward a diagnosis agreement and therapeutic approach.

Authors:  Branko N Huisa; Gary A Rosenberg
Journal:  Expert Rev Neurother       Date:  2014-09-09       Impact factor: 4.618

Review 2.  Blood and CSF biomarkers in brain subcortical ischemic vascular disease: Involved pathways and clinical applicability.

Authors:  A Vilar-Bergua; I Riba-Llena; C Nafría; A Bustamante; V Llombart; P Delgado; J Montaner
Journal:  J Cereb Blood Flow Metab       Date:  2016-01       Impact factor: 6.200

3.  Cerebrospinal fluid β-amyloid42 and neurofilament light relate to white matter hyperintensities.

Authors:  Katie E Osborn; Dandan Liu; Lauren R Samuels; Elizabeth E Moore; Francis E Cambronero; Lealani Mae Y Acosta; Susan P Bell; Michelle A Babicz; Elizabeth A Gordon; Kimberly R Pechman; L Taylor Davis; Katherine A Gifford; Timothy J Hohman; Kaj Blennow; Henrik Zetterberg; Angela L Jefferson
Journal:  Neurobiol Aging       Date:  2018-04-03       Impact factor: 4.673

4.  Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid.

Authors:  Per Selnes; Kaj Blennow; Henrik Zetterberg; Ramune Grambaite; Lars Rosengren; Lisbeth Johnsen; Vidar Stenset; Tormod Fladby
Journal:  Cerebrospinal Fluid Res       Date:  2010-07-30

Review 5.  Pathological Continuum From the Rise in Pulse Pressure to Impaired Neurovascular Coupling and Cognitive Decline.

Authors:  Olivia de Montgolfier; Nathalie Thorin-Trescases; Eric Thorin
Journal:  Am J Hypertens       Date:  2020-04-29       Impact factor: 2.689

6.  Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimer's Disease Pathology.

Authors:  Katie E Osborn; Jonathan M Alverio; Logan Dumitrescu; Kimberly R Pechman; Katherine A Gifford; Timothy J Hohman; Kaj Blennow; Henrik Zetterberg; Angela L Jefferson
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

7.  Significance of CSF NfL and tau in ALS.

Authors:  Stefanie Schreiber; Nicola Spotorno; Frank Schreiber; Julio Acosta-Cabronero; Jörn Kaufmann; Judith Machts; Grazyna Debska-Vielhaber; Cornelia Garz; Daniel Bittner; Nathalie Hensiek; Reinhard Dengler; Susanne Petri; Peter J Nestor; Stefan Vielhaber
Journal:  J Neurol       Date:  2018-09-05       Impact factor: 4.849

8.  Serum neurofilament light is sensitive to active cerebral small vessel disease.

Authors:  Thomas Gattringer; Daniela Pinter; Christian Enzinger; Thomas Seifert-Held; Markus Kneihsl; Simon Fandler; Alexander Pichler; Christian Barro; Svenya Gröbke; Margarete Voortman; Lukas Pirpamer; Edith Hofer; Stefan Ropele; Reinhold Schmidt; Jens Kuhle; Franz Fazekas; Michael Khalil
Journal:  Neurology       Date:  2017-10-18       Impact factor: 9.910

Review 9.  Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.

Authors:  Catherine Randall; Lisa Mosconi; Mony de Leon; Lidia Glodzik
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01

Review 10.  Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations.

Authors:  Sam T Creavin; Susanna Wisniewski; Anna H Noel-Storr; Clare M Trevelyan; Thomas Hampton; Dane Rayment; Victoria M Thom; Kirsty J E Nash; Hosam Elhamoui; Rowena Milligan; Anish S Patel; Demitra V Tsivos; Tracey Wing; Emma Phillips; Sophie M Kellman; Hannah L Shackleton; Georgina F Singleton; Bethany E Neale; Martha E Watton; Sarah Cullum
Journal:  Cochrane Database Syst Rev       Date:  2016-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.